Wednesday, April 23, 2025 4:40:24 PM
Seve, you're also only looking at today. I think Denner is trying to accomplish a number of things to increase valuation:
1. Continue building out EU pipeline and RoW.
2. Develop new label expansion, product, or combo story (ie. new formulation, GLP-1 oral combo story, authorized generic strategy, etc.)
3. Along with #2 above (via new formulation and AG), as well as with ongoing litigation, attempt to re-capture some or all of US market (and then the ability actually start marketing again).
There is a potential range of outcomes. If only #1 happens above, we'll see a modest multiple (2-3x) of projected EU revenue and RoW royalties. US revenue multiple would be modest, at best (again, this is assuming they cannot manage to re-capture any of the market). This would be the low-end/worst case, ~$2B buyout.
If they can expand the label, roll out the new formulation, establish a combination therapy, re-capture US market, or some combination of those, then the multiple will expand materially (6-8x or more is not unheard of) on a much higher projected revenue base. $5-8B is possible under this scenario.
If Denner did not think any of this was possible, they would have either cut their losses, or sold the company for $1-2B already. But I think his expectation is far beyond that.
Many people point to the Medicines Company deal, but I see it more closely resembling the Ariad/Takeda deal. He sold Ariad for $5.2B when it was doing 150-200M in revenue on Iclusig. A drug that had faced challenges from the FDA. It took 4-5 years for that deal to take place after Sarissa first got involved.
But Sarissa needs to have some of this in place (or at least in motion) before a max deal can take place. I think this is going to take another 18-24 months to come to fruition. Europe has just been much slower to evolve, and I am certain they want at least China and France under national reimbursement, as well as more clarity on their legal situation. They could also have the new formulation and AG on the table within that timeframe.
It's also my belief that Sarissa is hoarding cash (their own cash). I think there will come a point where a bunch of factors evolve at the same time (what was mentioned above, as well as Sarissa and/or Amarin buying shares) and we see some explosive SP growth. This will be the signal that a deal is heating up. They want to start shopping the company at a moment of strength, not weakness.
But...the lack of transparency/communication, and the stock price manipulation has been highly frustrating.
1. Continue building out EU pipeline and RoW.
2. Develop new label expansion, product, or combo story (ie. new formulation, GLP-1 oral combo story, authorized generic strategy, etc.)
3. Along with #2 above (via new formulation and AG), as well as with ongoing litigation, attempt to re-capture some or all of US market (and then the ability actually start marketing again).
There is a potential range of outcomes. If only #1 happens above, we'll see a modest multiple (2-3x) of projected EU revenue and RoW royalties. US revenue multiple would be modest, at best (again, this is assuming they cannot manage to re-capture any of the market). This would be the low-end/worst case, ~$2B buyout.
If they can expand the label, roll out the new formulation, establish a combination therapy, re-capture US market, or some combination of those, then the multiple will expand materially (6-8x or more is not unheard of) on a much higher projected revenue base. $5-8B is possible under this scenario.
If Denner did not think any of this was possible, they would have either cut their losses, or sold the company for $1-2B already. But I think his expectation is far beyond that.
Many people point to the Medicines Company deal, but I see it more closely resembling the Ariad/Takeda deal. He sold Ariad for $5.2B when it was doing 150-200M in revenue on Iclusig. A drug that had faced challenges from the FDA. It took 4-5 years for that deal to take place after Sarissa first got involved.
But Sarissa needs to have some of this in place (or at least in motion) before a max deal can take place. I think this is going to take another 18-24 months to come to fruition. Europe has just been much slower to evolve, and I am certain they want at least China and France under national reimbursement, as well as more clarity on their legal situation. They could also have the new formulation and AG on the table within that timeframe.
It's also my belief that Sarissa is hoarding cash (their own cash). I think there will come a point where a bunch of factors evolve at the same time (what was mentioned above, as well as Sarissa and/or Amarin buying shares) and we see some explosive SP growth. This will be the signal that a deal is heating up. They want to start shopping the company at a moment of strength, not weakness.
But...the lack of transparency/communication, and the stock price manipulation has been highly frustrating.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
